Soluble oncoprotein 185(HER-2) in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions

ArticleinClinical Biochemistry 38(11):1031-3 · November 2005with4 Reads
Impact Factor: 2.28 · DOI: 10.1016/j.clinbiochem.2005.05.001 · Source: PubMed
Abstract

To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for the diagnosis of malignant effusions. Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103 benign effusions. Thresholds of these tumor markers were chosen for a diagnostic specificity of >or=99%. Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of breast and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6. Combination of CEA and CA 15-3 resulted in 50% sensitivity, while adding sp185(HER-2) to this panel nonsignificantly increased sensitivity by 5% (P = 0.45). Only 1 patient with breast adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point. Measurement of pleural fluid sp185(HER-2) has poor diagnostic performance in patients with malignant effusions.